Phase 2 Macular Degeneration Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are able to undergo an eye surgery procedure with monitored sedation (rather than full general anaesthesia)
- People who have been diagnosed with geographic atrophy (a form of advanced age-related macular degeneration, or AMD)
- People whose vision in the study eye falls within a specific range when tested using a standard eye chart assessment called ETDRS (confirm with trial site for exact score details)
- People whose study eye has already had cataract surgery and has an artificial lens in place
Who may not be able to join:
- People who are pregnant or breastfeeding
- People with a history of cognitive impairment or dementia
- People with certain ongoing or serious health conditions that, in the investigator's opinion, could affect the safety of participation or make it harder to assess results accurately
- People who have any current or past eye disease (other than geographic atrophy) that could affect assessment of the central part of the retina
- People with a history of retinal detachment in the study eye
- People who have previously had vitreous eye surgery, glaucoma-filtering surgery, or a corneal transplant in the study eye
- People with uncontrolled or advanced glaucoma in the study eye
- People who have had cataract surgery or other eye surgery within 3 months before the study procedure
- People with other eye conditions that could make the investigational treatment risky or affect how results are interpreted
- People who have any existing device or implant in the back of the study eye
- For the substudy only: people with a past history of seizures or epilepsy of any kind, except for a single fever-related seizure in childhood
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Clinical Trials, Hoffmann-La Roche
Phone: 888-662-6728 (U.S. Only)
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Proportion of Participants With Subretinal Surgical Delivery of OpRegen to Target Regions; Incidence and Severity of Procedure-related Adverse Events (AEs) at 3 Months Following Surgery
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.